Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2007

View Archived Issues

Vinorelbine-cisplatin confirmed superior in stage II-IIIA NSCLC / News in Context

Eisai: Q3 report

Recent patents report new therapeutic agents for metabolic disorders

Recent Nissan Chemical patents describe new treatment options for thrombocytopenia

Axcan updates Q1 developments

ZymoGenetics' rhThrombin BLA accepted for review

SGX reviews oncology pipeline

Ark Therapeutics discusses phase III Vitor study with regulatory agencies

Valeant acquires rights to nabilone in the U.K. and Europe

KeyNeurotek and Max-Planck sign licensing agreement

Merck begins registrations of Atripla in developing countries

Inspire to commercialize AzaSite in U.S. and Canada

Gestiva reduces cervical shortening

Canarypox HIV vaccine responses in phase II not sufficient for phase III investigation

Pipex Pharmaceuticals' Coprexa awarded NIH grant for Alzheimer's disease

Post hoc subgroup analysis for Chrysalin in fracture repair

Safety, absorption of TMC-120 assessed in women with and without HIV

Traditional Chinese preparation to enter the clinic for the treatment of allergic asthma

New agents for treating neurological disorders disclosed in recent patents

Recent patents disclose novel treatments for diabetes

Cadherin-11: a potential target against rheumatoid arthritis

Cognitive and mood improvement after guarana therapy reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...